参考文献/References:
[1] 慕鹏莺,牛向宏.阿托伐他汀联合阿司匹林对急性脑梗死患者脑血流及颈动脉粥样斑块的影响[J].安徽医学,2016,37(9):1124-1126, 1127.
[2] 刘泽霖,贺石林,李家增.血栓性疾病的诊断与治疗[M].北京:人民卫生出版社,2000:422-428.
[3] Kozuda K,Kohriyama T,Nomllra E,et al.Endothelial markers and adhesion molecules in acute ischemic stroke:Sequential change and differences in stroke subtype[J].Atherosclerosis,2002,161(1):161-168.
[4] Hu HT,Fen F,Ding MP.Effects of puerarin with aspirin on the markers of damaged vascular endothelial cells in patients with acute cerebral infarction[J].Zhongguo Zhong Yao Za Zhi,2008,33(23):2827-2829.
[5] 叶青跃,程鹏飞,周有利,等.急性脑梗死患者血小板聚集功能、血管性血友病因子、抗凝血酶及 D-二聚体测定的临床意义[J].安徽医药,2015,19(2):309-310,311.
[6] Andersson HM,Siegerink B,Luken BM,et al.High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women[J].Blood,2012,119(6):1555-1560.
[7] Shi DM,Xia T,Feng HX,et al.Evaluating the diagnostic value of vWF:Ag, D-D and FDP in patients with acute cerebral infarction using ROC curves[J].Exp Ther Med,2014,7(6):1573-1577.
[8] 徐丛荣,魏建威,郑登滋,等.血管性血友病因子与急性脑梗死的相关性研究[J].医学理论与实践,2016,29(20):3450-3451.
[9] 王波,王海英,甘慧玲,等.瑞舒伐他汀对急性脑梗死患者血浆血管性假血友病因子和血栓调节蛋白水平的影响[J].实用药物与临床,2014,17(6):694-696.
[10] 徐颖.CD36、CD63和血管性血友病因子与急性脑梗死的相关性研究[D].苏州:苏州大学,2012.
[11] Pitto RP,Hamer H,Heiss-Dunlop W,et al.Mechanical prophylaxis of deep-vein thrombosis after total hip replacement-A randomised clinical trial[J].Journal of Bone and Joint Surgery-British Volume,2004,86B(5):639-642.
[12] 李武,谢小兵.急性脑梗死患者相关生化指标检测的临床意义[J].现代生物医学进展,2011,11(2):283-286.
[13] 马丽丽,何蕴,邢秀萍,等.急性脑梗死患者血清抗心磷脂抗体和血浆血栓烷B_2、6-酮-前列腺素_(1α)含量变化及其相互关系的研究[J].临床神经病学杂志,2006,19(4):281-283.
[14] 朱新岭,陈颖,杨君君,等.丁苯酞对急性脑梗死患者血管内皮功能的影响[J].中国慢性病预防与控制,2018,26(6):65-68.
[15] 陈聪,苏庆杰,吴海荣,等.丁苯酞注射液联合依达拉奉注射液治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2018,34(4):395-398.
[16] Zhang J,Yang J,Chang X,et al.Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials[J].Neurol Res,2012,34(4):346-353.
[17] An GH,Sim SY,Jwa CS,et al.Thromboxane a2 synthetase inhibitor plus low dose aspirin: can it be a salvage treatment in acute stroke beyond thrombolytic time window[J].J Korean Neurosurg Soc,2011,50(1):1-5.
[18] Wang Y,Mao L,Lin B,et al.The role of thromboxane A2 receptor gene promoter polymorphism in acute cerebral infarction[J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,2014,26(5):309.
[19] Gulba DC,Barth els M,Westhoff-Bleck M.Increased th rom bin levels during thrombolytic therapy in acute myocardial infarction[ J].Circulation,1991,83(3):937-944.
[20] Uchiyama S,Yamazaki M,Hara Y,et al.Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke[C].1997:535-541.
[21] Meng R,Li ZY,Ji X,et al.Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke[J].Clin Neurol Neurosurg,2011,113(5):380-386.
[22] 唐喜军,田文芳,金涛,等.急性脑梗死溶栓治疗中F1+2、TAT和D-二聚体的研究[J].检验医学与临床,2007,4(6):503-504.
[23] 邱丽君,顾青,汪维乐,等.急性脑梗死患者用药前后血浆生物分子的变化[J].上海交通大学学报(医学版),2007,27(3):333-335.
[24] 窦红菊,胡钧培,邹丽芳,等.急性脑梗死患者血栓前体蛋白、凝血酶抗凝血酶复合物和D-二聚体的检测及其临床意义[J].血栓与止血学,2004,10(3):115-116.
[25] 杜鹏,刘文静,黄友敏,等.急性脑梗死患者血浆抵抗素和血栓调节蛋白含量变化的意义[J].中华临床医师杂志(电子版),2009,3(8):1363-1366.
[26] 张立中,陈洪山,华俊,等.血浆D-二聚体、血栓调节蛋白联合检测对脑梗死患者的临床意义[J].国际检验医学杂志,2011,32(2):287-288.
[27] 马进,夏海平,马瑞.急性脑梗死患者血浆内皮损伤标志物的变化及其临床意义[J].中国老年学杂志,2016,36(23):5851-5853.
[28] Zhang XP,Hu Y,Hong M,et al.Plasma thrombomodulin, fibrinogen, and activity of tissue factor as risk factors for acute cerebral infarction[J].Am J Clin Pathol,2007,128(2):287-292.
[29] 纪蒙.血栓调节蛋白与脑梗死面积的关系[J].山东医药,2010,50(4):24-25.
[30] 于逢春,翟艳苓,刘艳,等.急性脑梗死患者血浆组织因子及血栓调节蛋白的研究[J].北京医学,2006,28(4):196-198.
[31] Nomura E,Kohriyama T,Kozuka K,et al.Significance of serum soluble thrombomodulin level in acute cerebral infarction[J].European Journal of Neurology,2004,11(5):329-334.
[32] 张琦.探讨辅助检查急性脑梗死生物标志物的实用性[D].天津:天津医科大学,2015.
[33] Yarnell JG,Sweetnam PM,Rumley A,et al.Lifestyle and hemostatic risk factors for ischemic heart disease:the caerphilly study[J].Arterioscler Thromb Vasc Biol,2000,20(1):271-279.
[34] Zunker P,Schick A,Padro T,et al.Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: Relation to stroke etiology[J].Neurol Res,1999,21(8):727-732.
[35] 唐智敏.进展性脑梗死患者血浆t-PA及PAI-1水平的变化及临床意义[J].脑与神经疾病杂志,2010,18(2):110-112.
[36] 卢波,韩莉,吕志昆,等.急性脑梗死患者血清炎性因子,t-PA,PAI-1变化规律及其意义[J].疑难病杂志,2015,14(09):906-909.
[37] Linfante I,Starosciak A K,Walker G R,et al.Predictors of poor outcome despite recanalization: a multiple regression analysis of the NASA registry[J].Journal of Neuro Interventional Surgery, 2016,8(3):224-229.
[38] 王禺,李秀娥,赵曼,等.急性脑梗死患者的NT-proBNP和Hcy及部分凝血纤溶指标变化的临床意义[J].现代检验医学杂志,2017,32(3):89-91.
[39] 王宽红.探讨急性脑梗死患者凝血纤溶指标与预后的关系[J].中国实用神经疾病杂志,2017,20(10): 73- 75.
[40] Ikeda M,Kan-No H,Hayashi M,et al.Predicting perioperative venous thromboembolism in Japanese gynecological patients[J].PLoS One,2014,9(2):e89206.
[41] 沈仙娣,方晶,严为宏.脑梗死急性期血栓调节蛋白、纤溶酶-抗纤溶酶复合物变化与内皮细胞损伤[J].中国临床康复,2004,8(19):3788-3789.
[42] 刘建荣,王桥根,王学峰.脑梗死患者急性期血浆纤维蛋白溶解标志物的变化[J].诊断学理论与实践,2004,3(2):120-121.
[43] Yamazaki M,Uchiyama S,Maruyama S.Alterations of haemostatic markers in various subtypes and phases of stroke[J].Blood Coagulation&Fibrinolysis An International Journal in Haemostasis&Thrombosis,1993,4(5):707.
[44] 王璐,钟琪,毕晓莹.急性脑梗死患者Hcy,ox-LDL,D-二聚体的表达水平及意义[J].安徽医学,2018,39(10):1268-1271.
[45] 何蕴,马丽丽,邢秀萍.进展性脑梗死急性期纤维蛋白原和纤溶指标的动态变化及其意义[J].血栓与止血学,2003,9(3):129-130.
[46] Ran Meng,Xuming Ji,Baoyu Li,et al.Dynamical level of plasma F1+2 and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis[J].Neurological Research,2009,31(4):367-370.
[47] Wang J,Ning RZ,Wang YP.Plasma D-dimer Level, the Promising Prognostic Biomarker for the Acute Cerebral Infarction Patients[J].Journal of Stroke & Cerebrovascular Diseases,2016,25(8):2011-2015.
[48] Hirano K,Takashima S,Dougu N,et al. Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype[J].Journal of Stroke & Cerebrovascular Diseases,2012,21(5):404-410.
[49] Rui W,Yamin W,Junfang T.Levels of plasma N-terminal pro-brain natriuretic peptide and D-dimer on the prognosis of patients with acute cerebral infarction[J].Pakistan Journal of Medical Sciences,2018,34(4):855-858.
[50] 黄攀,何晓英.D-二聚体,P选择素联合检测对急性脑梗死病情及预后判断的价值[J].中国老年学杂志,2018,38(24):5909-5911.
[51] 嵇朋,杨佳蕾,李小刚.血浆N末端B型钠尿肽前体和D-二聚体对急性脑梗死患者预后影响的研究[J].中华老年心脑血管病杂志,2018,20(10):1058-1061.
[52] 张卓,陶伟,王俊虎.急性脑梗死患者TOAST分型与血清同型半胱氨酸和D-二聚体水平的关系[J].心脑血管病防治,2018,18(5):423-424,427.
[53] 吴志勇,肖瑾,刘兵荣,等.血浆D-二聚体在心源性脑梗死患者中的表达[J].中国脑血管病杂志,2016,13(11):601-604.
[54] 余国庆,岳峰,杨炜炜.急性脑梗死患者检测胱抑素C、D-二聚体、纤维蛋白原及纤维蛋白(原)降解产物的意义[J].现代实用医学,2014,26(4):400-401.
[55] 徐革.血浆 D-二聚体和纤维蛋白原降解产物在急性脑梗死患者中的检测意义[J].河北医药,2014,36(8):1163-1165.
[56] 荀顺芹.血浆D-二聚体和纤维蛋白原降解产物检测在急性脑梗死患者中的临床意义[J].中国实用神经疾病杂志,2016,19(14):63-64.
[57] 李朝.纤维蛋白原降解产物和血浆D-二聚体在急性脑梗死患者中的检测意义[J].中国当代医药,2012,19(14):91-91.
[58] 冯红选.血管性血友病因子抗原、D-二聚体、纤维蛋白原降解产物与急性脑梗死的相关研究[D].苏州:苏州大学,2013.